Evidence map›Paper›PMID 33124129›Full record

ArticleCancer science2021

Suitability of transbronchial brushing cytology specimens for next-generation sequencing in peripheral lung cancer.

Naoki Furuya, Shingo Matsumoto, Kazutaka Kakinuma, Kei Morikawa, Takeo Inoue, Hisashi Saji, Koichi Goto, Masamichi Mineshita

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Future oncology (London, England) · 2025
    Review
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Absorbable cyst brushes.Biomedical microdevices · 2023
    Article
  9. Review
  10. Robotic Bronchoscopy: Review of Three Systems.Life (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Naoki FuruyaDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.ORCID https://orcid.org/0000-0001-7162-5946
Shingo MatsumotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kazutaka KakinumaDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Kei MorikawaDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Takeo InoueDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Hisashi SajiDepartment of Chest Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-3023-2510
Masamichi MineshitaDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
St. Marianna University School of Medicine · JPNational Cancer Center Hospital East · JP

Funding

AmgenAstellasAstraZenecaBoehringer-IngelheimBristol-MyersChugaiDaiichi-SankyoEisaiEli LillyJanssenKyowa KirinMBLMerck SeronoMSDNovartisOnoPfizerSumitomo DainipponTaihoTakeda
6 · The paper itself

Abstract

Next-generation sequencing (NGS) enables the diagnosis of large numbers of gene aberrations during one examination, and precision medicine has been developed for patients with advanced non-small cell lung cancer (NSCLC). However, peripheral lung lesions account for the majority of advanced lung cancers, especially lung adenocarcinoma. In these cases, it is difficult to obtain tissue samples which contain sufficient tumor cells by transbronchial biopsy (TBB) with forceps. Even when the target lesions are quite small, bronchial brushing can obtain enough tumor cells by endobronchial ultrasonography using guide sheath (EBUS-GS). In this study, we investigate the suitability of bronchial brushing cytology specimens obtained by EBUS-GS-TBB to evaluate the correlation between the success rate of NGS and extracted DNA/RNA yields according to biopsy method. We prospectively collected 222 tumor samples obtained from patients with advanced lung cancer. All patients were enrolled in a prospective nationwide genomic screening project for lung cancer (LC-SCRUM-Japan/Asia). Genomic data were obtained from the clinico-genomic database of LC-SCRUM-Japan/Asia. The extraction yields of DNA/RNA from samples obtained by EBUS-GS-TBB were relatively low compared with tissue samples. The success rate of DNA sequencing for EBUS-GS-TBB was 97.9%, with no significant differences between biopsy methods. The success rate of RNA sequencing for EBUS-GS-TBB was 80.4%, which was relatively low compared with surgical biopsy samples (P = 0.069). However, some rare oncogenic driver aberrations were detected from these specimens. This study demonstrated that cytology samples obtained by transbronchial brushing with EBUS-GS-TBB were suitable for NGS analysis.

Indexed as

High-Throughput Nucleotide SequencingAdultAgedAged, 80 and overBiopsy, NeedleBronchoscopyCarcinoma, Non-Small-Cell LungFemaleHumansImage-Guided BiopsyLung NeoplasmsMaleMiddle AgedUltrasonography, Interventionalbronchial brushinglung cancernext-generation sequencingnucleic acid yieldsuccess rate

Identifiers

PMID33124129
PMCPMC7780058
OpenAlexW3095289944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.